An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

One dose of an experimental drug cover offer lifetime treatment for people with high cholesterol, but its long-term safety is ...

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a -2.56% change from its previous close.

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...

Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.

The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...

In a phase 1 trial, a gene-editing therapy that targets ANGPTL3 was associated with few serious adverse events and at higher ...

A cutting-edge medical experiment in a small trial has demonstrated the effectiveness of a one-time CRISPR gene editing treatment in lowering cholesterol levels ...

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like ...

Scientists at Georgia State University have used CRISPR gene editing to restore an ancient enzyme humans lost millions of years ago potentially reversing the buildup of uric acid that causes gout.

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...